Itolizumab was associated with high clinical response rates at Day 15 and 29Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif. (BUSINESS WIRE) $EQ #GVHD Equillium, Inc.
Home / Top News / Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial
reduction in baseline corticosteroid use
Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with itolizumab mechanism of action
LA JOLLA, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a first-line treatment for acute g